Job creations
The new R&D facility is a product of its new licensing deal with BridgeBio Pharma and will operate under Helsinn Therapeutics.
When the two new sites are up and running, Eli Lilly predicted the project will create up to 500 new jobs - with the expectation of four indirect jobs for each full-time position, based on industry data.
Most of Samsung’s investment will be in South Korea, and it expects to create 80,000 new jobs through 2026, or about 16,000 positions annually.
Virongy is expanding again and has committed to a $471,000 expansion with up to 70 new jobs.
Vertex Pharmaceuticals dedicated a new site in Boston’s Seaport. But the company seemed to say, “But wait! There’s more!” and announced it plans to build another facility in the area.
ImmunoGen, which is developing Antibody-drug conjugates (ADCs) for the treatment of cancer, is on a hiring spree. The company is looking to hire for more than 200 positions by the end of 2022.
Over the past several years, The Lone Star State has been growing in significance as a life sciences hub. Now the industry is flocking to Hays County and its Innovation Corridor.
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
Moderna has made the official request to the FDA to approve its COVID-19 for use in children ages 6 months to 5 years. Moderna also announced the location of its first non-U.S. mRNA manufacturing facility.
Seagen, Inc. and NovoCure Ltd. have each announced plans to open new facilities in the coming years, expanding local employment opportunities and respective presences in the biotech industry.
PRESS RELEASES
